%0 Journal Article
%T Patient-reported outcomes of ocriplasmin for the treatment of vitreomacular traction: a systematic review and synthesis of the literature
%A Benedicte Lescrauwaet
%A Koenraad Blot
%A Timothy L Jackson
%J Archive of "Patient Related Outcome Measures".
%D 2019
%R 10.2147/PROM.S153718
%X Vitreomacular traction (VMT) is a disease in which the vitreous exerts abnormally strong traction on the macula, the area of the eye responsible for detailed central vision. If this traction significantly distorts the macula then VMT can lead to troublesome distorted vision (metamorphopsia), sometimes occurring despite relatively preserved visual acuity. Ocriplasmin, administered as a single intravitreal injection, aims to release VMT and improve vision. While the effect of ocriplasmin on traction release and visual acuity is well characterized, the effect of symptoms like metamorphopsia is not
%K macular hole
%K metamorphopsia
%K patient reported outcomes
%K symptomatic vitreo-macular adhesion
%K vitreomacular traction
%K visual function questionnaire
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443223/